EPISODE · Mar 11, 2026 · 12 MIN
Barclays Miami: Zealand Pharma CEO Adam Steensberg makes the case for last week's amylin data
from BiotechTV - News · host BiotechTV
He argues that investors are too focused on each percentage of weight loss and not focused enough on the tolerability of new options. He discusses the timeline for the phase 3 that will likely start later this year, and how it might look different than the phase 2 study that just read out.
What this episode covers
He argues that investors are too focused on each percentage of weight loss and not focused enough on the tolerability of new options. He discusses the timeline for the phase 3 that will likely start later this year, and how it might look different than the phase 2 study that just read out.
NOW PLAYING
Barclays Miami: Zealand Pharma CEO Adam Steensberg makes the case for last week's amylin data
No transcript for this episode yet
Similar Episodes
Apr 21, 2026 ·13m
Apr 19, 2026 ·16m
Apr 17, 2026 ·13m
Apr 13, 2026 ·11m
Apr 11, 2026 ·16m